Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.

scientific article published in November 2002

Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/DMRR.324
P698PubMed publication ID12469362
P5875ResearchGate publication ID6972902

P50authorMarja-Riitta TaskinenQ18246437
P2093author name stringAnja Schweizer
James E Foley
Juha Vakkilainen
Niina Mero
P2860cites workDiabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levelsQ34386174
Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistanceQ34399523
Analysis of serial measurements in medical researchQ35167613
An immunochemical method for the selective measurement of two triglyceride lipases in human postheparin plasmaQ40341530
Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart diseaseQ40677577
Repeated measurements and multiple comparisons in cardiovascular researchQ40748707
Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery diseaseQ40810473
Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166).Q41140104
Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetesQ43618975
Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart StudyQ44049495
Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial InfarctionQ44144342
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.Q44689759
Postprandial elevation of ApoB-48-containing triglyceride-rich particles and retinyl esters in normolipemic males who smoke.Q51573174
Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM.Q51574301
Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistanceQ51590571
Modulation of low density lipoprotein subclasses by alimentary lipemia in control and normotriglyceridemic non-insulin-dependent diabetic subjectsQ71858705
Defective regulation of triglyceride metabolism by insulin in the liver in NIDDMQ73250750
Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitusQ73718604
Glucose intolerance in familial combined hyperlipidaemia. EUFAM study groupQ74313811
P433issue6
P921main subjecttype 2 diabetesQ3025883
P304page(s)484-490
P577publication date2002-11-01
P1433published inDiabetes - Metabolism: Research and ReviewsQ15750056
P1476titleEffects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes
P478volume18

Reverse relations

cites work (P2860)
Q44744484A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes
Q89586580Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study
Q51475245Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
Q73210876Current literature in diabetes
Q35139885Diabetic dyslipidaemia: from basic research to clinical practice.
Q40535355Early alterations in the postprandial VLDL1 apoB-100 and apoB-48 metabolism in men with strong heredity for type 2 diabetes.
Q51381989Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
Q44236773Effect of three consecutive meals on the physicochemical properties of HDL and LDL in individuals with the metabolic syndrome and patients with type 2 diabetes
Q46368028Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test
Q26862823Impact of postprandial glycaemia on health and prevention of disease
Q47318058Impact of postprandial lipaemia on low-density lipoprotein (LDL) size and oxidized LDL in patients with coronary artery disease
Q36349994Low-density lipoprotein size and cardiovascular risk assessment.
Q36343495New insight into the pathophysiology of lipid abnormalities in type 2 diabetes
Q45277368No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes
Q35521022Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes
Q39101008Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes
Q44980056Restoration of early insulin secretion after a meal in type 2 diabetes: effects on lipid and glucose metabolism
Q46044954Sustained postprandial decrease in plasma levels of LDL cholesterol in patients with type-2 diabetes mellitus
Q46905943The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients.
Q51495360Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.